According to Markntel Advisors Report, Hepatocellular Carcinoma (HCC) Market is expected to grow at a significant growth rate, and the analysis period is 2022-2027, considering the base year as 2021.Consistent monitoring and evaluating of market dynamics to stay informed and adapt your strategies accordingly. As a market research and consulting firm, we offer market research reports that focus on major parameters including Target Market Identification, Customer Needs and Preferences, Thorough Competitor Analysis, Market Size & Market Analysis, and other major factors. At the end, we do provide meaningful insights and actionable recommendations that inform decision-making and strategy development.

Hepatocellular Carcinoma (HCC) is a liver malignancy that emerges in liver cells and is the sixth most common cancer worldwide. It is the third most cause of cancer-related deaths globally, with prominent risk factors, including excessive alcohol consumption, HBV (Hepatitis B Virus) & HCV (Hepatitis C Virus) infections, and other lifestyle disorders.

Hepatocellular Carcinoma (HCC) Market Research Report & Summary:

The Global Hepatocellular Carcinoma (HCC) Market is projected to grow at a CAGR of around 10.20% during the forecast period, i.e., 2022-27.                 

Time Period Captured in the Report:

·        Historical Years: 2017-20

·        Base Years: 2021

·        Forecast Years: 2022-27 

Who are the Key Players Operating in the Hepatocellular Carcinoma (HCC) Market?

The top companies of the Hepatocellular Carcinoma (HCC) Market ruling the industry are: 

Amgen Inc., AstraZeneca plc, Bayer AG, BeiGene, Bristol Myers Squibb, Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, Pfizer Inc.

✅In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report. 

Access the detailed PDF Sample report – https://www.marknteladvisors.com/query/request-sample/hepatocellular-carcinoma-hcc-market.html

("Kindly use your official email ID for all correspondence to ensure seamless engagement and access to exclusive benefits, along with prioritized support from our sales team.")

What is Included in Hepatocellular Carcinoma (HCC) Market Segmentation?

The Hepatocellular Carcinoma (HCC) Market explores the industry by emphasizing the growth parameters and categorizes including geographical segmentation, to offer a comprehensive understanding of the market dynamic.  The further bifurcations are as follows:

• By Diagnosis
• Blood Tests
• AFP (Alfa-Fetoprotein)
• LFT (Liver Function Test)
• Hepatic Angiography
• Liver Biopsy
• Laparoscopy
• Others (MRI, CT scan, etc.)
• By Treatment
• Chemotherapy
• Cisplatin
• Gemcitabine (Gemzar)
• Oxaliplatin (Eloxatin)
• Doxorubicin (pegylated liposomal doxorubicin)
• 5-fluorouracil (5-FU)
• Immunotherapy
• Atezolizumab (Tecentriq)
• Pembrolizumab (Keytruda)
• Nivolumab (Opdivo)
• Ipilimumab (Yervoy)
• Surgery
• Hepatectomy
• Liver Transplant
• Radiation Therapy
• Targeted Therapy
• Kinase Inhibitors
• Sorafenib
• Lenvatinib
• Regorafenib (Stivarga)
• Cabozantinib (Cabometyx)
• Monoclonal Antibodies
• Bevacizumab (Avastin)
• Ramucirumab (Cyramza)
• By End-User
• Hospitals
• Cancer Centers
• Others (Ambulatory Surgery Centers, etc.)
• By Region
• North America
• South America
• Europe
• Middle East & Africa
• Asia-Pacific

 Explore the Complete Hepatocellular Carcinoma (HCC) Market Analysis Report – https://www.marknteladvisors.com/research-library/hepatocellular-carcinoma-hcc-market.html

Market Segmentation

Based on Treatment:

• Chemotherapy
• Cisplatin
• Gemcitabine (Gemzar)
• Oxaliplatin (Eloxatin)
• Doxorubicin (pegylated liposomal doxorubicin)
• 5-fluorouracil (5-FU)
• Immunotherapy
• Atezolizumab (Tecentriq)
• Pembrolizumab (Keytruda)
• Nivolumab (Opdivo)
• Ipilimumab (Yervoy)
• Surgery
• Hepatectomy
• Liver Transplant
• Radiation Therapy
• Targeted Therapy
• Kinase Inhibitors
• Sorafenib
• Lenvatinib
• Regorafenib (Stivarga)
• Cabozantinib (Cabometyx)
• Monoclonal Antibodies
• Bevacizumab (Avastin)
• Ramucirumab (Cyramza)

Of all treatments, targeted therapy drugs like Sorafenib & Lenvatinib (kinase inhibitors) led the Global Hepatocellular Carcinoma (HCC) Market in previous years. For many years, they have been the SOC (standard of care) treatment of patients with advanced HCC. Sorafenib is oral bi-aryl urea that inhibits multiple cell surface & downstream kinases involved in tumor progression. Phase 3 randomized placebo-controlled trials conducted across regions like the Americas, Asia, & Europe made Sorafenib a preferred systematic therapy for advanced HCC. It was due to improved OS (overall success) rates in patients, coupled with mild to moderate severity of toxicities, such as hand-foot skin reactions, fatigue, & diarrhea.

However, in May 2020, FDA approved the combination of Avastin (bevacizumab) & Tecentriq (atezolizumab) as the first-line treatment for patients suffering from metastatic or unresectable hepatocellular carcinoma. The combination therapy, i.e., only for those with no history of any systemic therapy, showed enhanced efficacy & safety compared to kinase inhibitors and is projected to dominate the Global Hepatocellular Carcinoma (HCC) Market throughout 2027.

Need personalized insights? Click here to customize this report- https://www.marknteladvisors.com/query/request-customization/hepatocellular-carcinoma-hcc-market.html

Why Markntel Advisor Report?

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.

For Further Queries:

Contact Us

MarkNtel Advisors

Email at -[email protected]

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh - 201271, India